{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:57Z","timestamp":1789726257732,"version":"4.0.1"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor which received U.S. Food and Drug Administration approval in 2013 for the treatment of type 2 diabetes mellitus. Fanconi syndrome is a rare acquired disorder which typically occurs in adults as an adverse effect of medications. The literature includes few case reports of Fanconi syndrome caused by the use of canagliflozin. Here, we present a case of Fanconi syndrome in a patient with type 1 diabetes previously miscategorized as type 2 diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 32-year-old woman with a 6-year history of type 2 diabetes was started on canagliflozin. Within 2 months of therapy initiation, she began to develop symptoms of high anion gap metabolic acidosis. Further laboratory test results showed severe life-threatening hypophosphatemia. Further investigation by nephrology revealed the presence of Fanconi syndrome. During the admission, she was found to have clinical and laboratory features of type 1 (insulin-dependent) diabetes. After discontinuation of canagliflozin, she was treated with intravenous (i.v.) fluids for hydration, subcutaneous insulin, and i.v. potassium phosphate. She recovered from all metabolic acidosis and electrolyte abnormalities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Fanconi syndrome is a rare, exogenously acquired disorder in adults that often develops as an adverse effect of medication therapy. Our patient presented with Fanconi syndrome as a complication of canagliflozin use for the treatment of presumed type 2 diabetes. She was then started on subcutaneous insulin monotherapy for the treatment of type 1 diabetes mellitus.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxz226","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T15:58:36Z","timestamp":1573660716000},"page":"1930-1933","source":"Crossref","is-referenced-by-count":7,"title":["Canagliflozin-induced Fanconi syndrome in a patient with previously unrecognized type 1 diabetes"],"prefix":"10.1093","volume":"76","author":[{"given":"Naseer","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Nephrology, Ochsner Medical Center, Baton Rouge, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Tso","sequence":"additional","affiliation":[{"name":"Ochsner Medical Center, Baton Rouge, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Broussard","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ochsner Medical Center, Baton Rouge, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Dziuba","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ochsner Medical Center, Baton Rouge, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"2019111315583098000_CIT0001","article-title":"Fanconi syndrome","author":"Kaplan","year":"2018","edition":"20th ed."},{"key":"2019111315583098000_CIT0002","article-title":"Fanconi syndrome","author":"Fathallah-Shaykh","year":"2018","journal-title":"Medscape."},{"key":"2019111315583098000_CIT0003","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes."},{"key":"2019111315583098000_CIT0004","author":"Johnson & Johnson"},{"key":"2019111315583098000_CIT0005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1310\/hpj5009-756","article-title":"Nonconvulsive status epilepticus in elderly patients receiving SSRIs; euglycemic diabetic ketoacidosis associated with canagliflozin use in a type 1 diabetic patient; duloxetine-induced galactorrhea; canagliflozin-associated severe hypercalcemia and hypernatremia; vemurafenib-induced Fanconi syndrome","volume":"50","author":"Mancano","year":"2015","journal-title":"Hosp Pharm."},{"key":"2019111315583098000_CIT0006","doi-asserted-by":"crossref","first-page":"232470961771273","DOI":"10.1177\/2324709617712736","article-title":"Euglycemic diabetic ketoacidosis with prolonged glucosuria associated with the sodium-glucose cotransporter-2 canagliflozin","volume":"5","author":"Kelmenson","year":"2017","journal-title":"J Investig Med High Impact Case Rep."},{"key":"2019111315583098000_CIT0007","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/nep.13094","article-title":"Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin","volume":"23","author":"Esprit","year":"2018","journal-title":"Nephrology."},{"key":"2019111315583098000_CIT0008","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1053\/j.ajkd.2016.03.330","article-title":"A case of Fanconi syndrome in a patient taking canagliflozin for diabetes: a previously unreported catastrophic adverse effect","volume":"67","author":"Shawwa","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2019111315583098000_CIT0009","article-title":"Diabetic ketoacidosis","author":"Kaplan","year":"2018","edition":"20th ed."},{"key":"2019111315583098000_CIT0010","author":"INVOKANA (canagliflozin)","year":"2013"},{"key":"2019111315583098000_CIT0011","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s13300-017-0265-4","article-title":"A practical review of C-peptide testing in diabetes","volume":"8","author":"Leighton","year":"2017","journal-title":"Diabetes Ther."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/23\/1930\/30696412\/zxz226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/23\/1930\/30696412\/zxz226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T15:58:40Z","timestamp":1573660720000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/23\/1930\/5624092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":11,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2019,11,13]]},"published-print":{"date-parts":[[2019,11,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz226","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,1]]},"published":{"date-parts":[[2019,11,13]]}}}